In May 2026, Academician Han Zhongchao — founder of Han's United and the scientific lead behind stemcell-china.com — was once again included in the international "Top 100,000 Scientists Worldwide 2026" ranking, published by the analytical platform Tongzhou Cloud Academic. According to the aggregator, his H-index stands at 71, with 393 indexed publications. Among leading hematology researchers in China, the academician holds 8th place.
What is the «Top 100,000 Scientists Worldwide» ranking
Tongzhou Cloud Academic (同舟云学术, formerly Global Scholar Library) is a Chinese scientific analytics platform that aggregates more than 170 million articles from peer-reviewed international journals across all major scientific disciplines.
The ranking is built without input from the scientists themselves: an algorithm evaluates every publication along four independent dimensions — journal quality, publication type, citation count, and author contribution to the work. The sum of these scores across all of a researcher's publications produces their overall score. The top ten percent on this measure form the "Top 100,000" list.
This is neither an award nor a reputation poll. It is a machine-driven aggregation of global research output across a scholar's entire career — a measurement of how widely their work is actually used by other researchers in their own publications.
Academician Han Zhongchao's metrics in the 2026 ranking
- H-index — 71
- Indexed publications — 393
- Total article citations — 16,585
- Citations as first author — 6,861
- Position in China (Hematology) — 8th of 24
- Global rank in the overall list — 45,937
- Affiliation in the ranking — Chinese Academy of Medical Sciences, Institute of Hematology, Experimental Center
An H-index of 71 means the author has at least 71 scientific papers, each of which has been cited by other researchers no fewer than 71 times. This metric does not measure raw publication volume — it measures the proportion of an author's work that has entered active scientific use.
For comparison: the average H-index of a working biomedicine professor falls between 20 and 30. Values above 60 in this field are rare and typically belong to scientists whose discoveries underpin entire research directions or clinical protocols.
It is worth noting that Academician Han Zhongchao has an even higher figure from a separate source: in Stanford University's 2022 list of the world's Top-2% scientists, his H-index was reported as 81. Different platforms use different time windows and citation databases, hence the discrepancy. Both figures confirm the same conclusion: the scope of his research contribution is widely recognised.
China's Top 10 Hematologists and the Academician's Place Among Them
The "Hematology — China" list in the 2026 ranking contains 24 names. This is a dense, competitive slice: every name on the list is tied to a major research programme. Among the top ten alongside Academician Han Zhongchao:
- Huang Xiaojun (Peking University, People's Hospital, Institute of Hematology Research) — 1st place
- Chen Saijuan (Shanghai Jiao Tong University, Ruijin Hospital) — 4th place
- Chen Zhu (Shanghai Jiao Tong University, Ruijin Hospital) — 5th place
- Huang He (Zhejiang University, First Affiliated Hospital) — 7th place
- Han Zhongchao (Chinese Academy of Medical Sciences, Institute of Hematology) — 8th place
Career milestones: 600+ papers, 30+ awards, 9 therapeutics in clinical trials
The academician's credentials have accumulated over more than 40 years of work:
- Member of the French National Academy of Technologies (Académie nationale des technologies)
- Member of the French National Academy of Medicine (Académie nationale de médecine)
- Director of the National Engineering and Technical Research Center for Stem Cells (China)
- Chairman of the Board of Han's United (Beijing Hanshi United Biotechnology)
Career totals as of 2026: more than 600 published works, approximately 400 of them in international SCI journals. Around 20 books (as author and co-author, in Chinese and English). More than 20 patents on inventions. Over 30 scientific awards at the national and international level.
The principal applied result — 9 Han's United-developed Class I stem cell therapeutics have received clinical trial approval simultaneously from NMPA (China) and ANSM (France). Class I designates a new compound, not a generic — a rare status in the biotech industry, especially with dual regulatory validation.
What this means for patients of stemcell-china.com
When a patient or a patient's family chooses a clinic for a stem cell procedure, the central question is what scientific foundation underpins the treatment protocols. A marketing claim like "we use advanced technologies" says nothing. A machine-aggregated international ranking does.
Han's United is not only a clinical infrastructure (7 cell banks across China, ISO 9001:2015, CMA accreditation, 2 laboratories with CNAS) — it is also a scientific school that grew around the research programme of its founder. The protocols and standards under which the clinical base in Shangrao operates rest on 40 years of work by the academician and his team in hematology, vascular biology, and regenerative medicine.
Learn more about the clinic's founder — full profile of Academician Han Zhongchao.
Have a question about stem cell treatment? Book a consultation via our contact form.
The re-inclusion of Academician Han Zhongchao in the "Top 100,000 Scientists Worldwide 2026" ranking confirms that the scientific foundation of Han's United remains one of the strongest in global regenerative medicine. For patients, this means that the treatment protocols and safety standards in operation at the clinic rest on a continuously updated international research base — not on outdated or unverified methods.
Source: official WeChat publication of Han's United (汉氏联合) dated 14 May 2026. Primary source for the ranking: Tongzhou Cloud Academic (同舟云学术), «2026 Top 100,000 Scholars».